Patents by Inventor David Dong Eun Chang

David Dong Eun Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy
    Patent number: 8980259
    Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an insulin-like growth factor-1 receptor (IGF1R) inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignees: Novartis AG, Amgen, Inc.
    Inventors: Xizhong Huang, Malte Peters, Karl Maria Schumacher, Zhu Alexander Cao, Jennifer Lorraine Gansert, David Dong Eun Chang
  • Combination therapy
    Patent number: 8961970
    Abstract: The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 24, 2015
    Assignees: Novartis AG, Amgen Inc.
    Inventors: Xizhong Huang, Malte Peters, Jennifer Lorraine Gansert, David Dong Eun Chang, Pedro Beltran, Zhu Alexander Cao
  • COMBINATION THERAPY
    Publication number: 20140023661
    Abstract: The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 23, 2014
    Applicants: Amgen, Inc., Novartis Pharma AG
    Inventors: Xizhong Huang, Malte Dong Eun Peters, Karl Maria Schumacher, Zhu Alexander Cao, Jennifer Lorraine Gansert, David Dong Eun Chang
  • COMBINATION THERAPY
    Publication number: 20130273061
    Abstract: The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 17, 2013
    Applicants: Amgen, Inc., Novartis Pharma AG
    Inventors: Xizhong Huang, Malte Peters, Jennifer Lorraine Gansert, David Dong Eun Chang, Pedro Beltran